Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

INSIDE INFORMATION UPDATE ANNOUNCEMENT IN RELATION TO JUDGMENT

This announcement is made by the board of directors (the "**Board**") of Wai Chun Bio-Technology Limited (the "**Company**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the Company's announcement dated 25 February 2026 (the "**Announcement**") relating to the Judgment. Terms used herein shall have the same meanings as defined in the Announcement unless otherwise stated.

UPDATE ON THE JUDGMENT

The Board wishes to update the shareholders and potential investors of the Company that on 30 April 2026, the Company and the First Defendant have jointly paid HK$4,190,000 to the Plaintiff as a global settlement. Messrs. Vincent T.K. Cheung, YAP & Co., solicitors for the Plaintiff and Messrs. P.C. Woo & Co., solicitors for the First Defendant and the Company, have signed a consent summons dated 30 April 2026 to seek an order by consent that, inter alia, leave be granted for the appeal against the Judgment as well as the Summons to adduce new evidence be dismissed, and the hearing of the New Evidence Summons and Notice of Appeal at the High Court of Hong Kong on 11 June 2026 and 5 August 2026 be vacated (the "**Consent Summons**"). The Consent Summons has been filed in the High Court of Hong Kong.

The Company will make further announcement once receive an order in terms of the Consent Summons from the High Court of Hong Kong.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman

Hong Kong, 7 May 2026

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer), and three independent non-executive directors, namely Mr. Wong Po Keung, Ms. Xu Huiling and Mr. Wang Ziniu.